PDF: Vivacity-MG3
(2024)Objective
Nipocalimab (anti-FcRn IgG1 mAb) at 4 doses vs placebo — to evaluate safety, efficacy, PK/PD over 8 weeks in adults with generalized myasthenia gravis inadequately controlled on standard-of-care therapy.
Study Summary
• Highest dose (60 mg/kg Q2W) reduced IgG by 83% at peak — robust target engagement.
• Mean MG-ADL change: placebo -1.8, 5 mg/kg -2.5, 30 mg/kg -3.9, 60 mg/kg Q2W -3.9.
• MG-QoL-15r significantly better for 30 mg/kg Q4W vs placebo (LSM diff -5.1; p=0.005).
• No deaths, no AEs of special interest (grade ≥3 infection or hypoalbuminemia), similar TEAE rates.
• Anti-drug antibodies in 40.7% but transient and did not affect PK/PD or efficacy; supports phase 3 development.
Intervention
IV nipocalimab in one of 4 regimens vs placebo over 8 weeks, all administered Q2W for blinding (with placebo on non-active weeks for Q4W and single-dose arms): (1) placebo Q2W, (2) 5 mg/kg Q4W, (3) 30 mg/kg Q4W, (4) 60 mg/kg single dose, (5) 60 mg/kg Q2W.
Inclusion Criteria
Adults ≥18 with gMG confirmed by anti-AChR or anti-MuSK antibodies, QMG ≥12 and MG-ADL ≥4 despite stable SOC, MGFA class II/III/IVa. Exclusions: biologic within 12 months, PLEX/IVIG within 6 weeks, recent rituximab or eculizumab, unresected thymoma.
Study Design
Arms: Placebo Q2W vs Nipocalimab 5 mg/kg Q4W vs 30 mg/kg Q4W vs 60 mg/kg single dose vs 60 mg/kg Q2W
Patients per Arm: Placebo 14; 5 mg/kg 14; 30 mg/kg 13; 60 mg/kg single 13; 60 mg/kg Q2W 14
Outcome
• MG-ADL LSM change from baseline: placebo -2.4, 5 mg/kg -2.4 (p=0.99), 30 mg/kg -3.7 (p=0.24), 60 mg/kg single -1.4 (p=0.36), 60 mg/kg Q2W -3.7 (p=0.22)
• IgG reduction: up to 83% with 60 mg/kg Q2W; dose-dependent and matched by anti-AChR reduction
• TEAEs 78.6% placebo vs 83.3% combined nipocalimab; no deaths, no discontinuations, no grade ≥3 AESI
• Anti-drug antibodies in 40.7%, low-titer and transient, no effect on PK/PD/efficacy/safety
Clinical Question
In adults with generalized myasthenia gravis and inadequate response to standard-of-care therapy, does the anti-FcRn monoclonal antibody nipocalimab demonstrate a dose-dependent reduction in MG-ADL total score at day 57 compared with placebo?
Bottom Line
In 68 gMG patients (94% anti-AChR+) randomized 1:1:1:1:1 to placebo or one of 4 IV nipocalimab regimens (5 mg/kg Q4W, 30 mg/kg Q4W, 60 mg/kg single-dose, or 60 mg/kg Q2W), a statistically significant dose-response was observed for MG-ADL change at day 57 (linear trend p=0.031). Individual pairwise comparisons vs placebo were not significant at this phase 2 sample size, but dose-dependent IgG reduction (up to 83%) and target engagement supported progression to phase 3 Vivacity-MG3.
Major Points
- Multicenter phase 2 double-blind placebo-controlled dose-ranging RCT at 38 sites in 8 countries (Antozzi/Guptill 2024)
- N=68 patients randomized 1:1:1:1:1 to placebo or one of 4 nipocalimab regimens (5/30/60 mg/kg Q4W or 60 mg/kg Q2W)
- All infusions Q2W over 8 weeks to maintain blinding (5 total infusions, days 1/15/29/43/57)
- 94.1% anti-AChR+, 6% anti-MuSK+; all on stable SOC (AChE-I 91%, steroids 68%, non-steroidal IS 41%)
- Primary efficacy: MG-ADL change from baseline to day 57
- Significant dose-response: linear trend p=0.031 across placebo/5/30/60 mg/kg Q2W (60 mg/kg single dose excluded from trend)
- Pairwise tests not significant at this sample size but trending in favor of higher doses
- IgG reduction: 83% maximal at 60 mg/kg Q2W; proportional to anti-AChR autoantibody reduction
- MG-QoL-15r significantly better at 30 mg/kg Q4W vs placebo (p=0.005, though not adjusted for multiplicity)
- Safety: TEAEs 83% vs 78.6% (combined nipocalimab vs placebo); no grade ≥3 AESI (infection or hypoalbuminemia), no deaths, no treatment discontinuations
- ADA positive 40.7%, mostly transient and low-titer; no effect on PK, PD, efficacy, or safety
- Supported progression to phase 3 Vivacity-MG3 (NCT04951622), which subsequently led to FDA approval of nipocalimab (Imaavy) for gMG in 2025
Study Design
- Study Type
- Multicenter double-blind placebo-controlled phase 2 dose-ranging RCT (NCT03772587)
- Randomization
- Yes
- Blinding
- Double-blind (patients, investigators, sponsor blinded); unblinded site pharmacist prepared infusions
- Sample Size
- 68
- Follow-up
- 4-wk screening + 8-wk treatment + 8-wk post-treatment follow-up
Primary Outcome
Definition: Dose-response for MG-ADL total score change from baseline to day 57 (linear trend test)
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| -1.8 (SD 3.22); LSM -2.4 (SE 0.9) | LSM -2.4 (5 mg/kg), -3.7 (30 mg/kg Q4W), -1.4 (60 mg/kg single), -3.7 (60 mg/kg Q2W) | - (Not explicit for trend) | Linear trend p=0.031; rank-based p=0.004 |
Limitations & Criticisms
- Small phase 2 sample (n=13-14 per arm) limits power to detect pairwise differences; only the linear trend was significant
- COVID-19 pandemic disrupted QMG assessments (requires in-person evaluation), limiting QMG endpoint interpretation
- 8-week treatment period is short; sustained efficacy and durability require phase 3 data
- Only 4 anti-MuSK patients enrolled — insufficient for MuSK-specific conclusions
- MG-QoL-15r benefit with 30 mg/kg (p=0.005) but not higher doses may reflect chance given multiple comparisons without multiplicity adjustment
- Class I evidence rating reflects the statistically significant dose-response; pairwise comparisons were hypothesis-generating only